Source: iQoncept / Shutterstock
ARS Pharmaceuticals (NASDAQ:SPRY) just reported results for the first quarter of 2024.
- ARS Pharmaceuticals reported earnings per share of -11 cents. This met the analyst estimate for EPS of -11 cents.
- The company did not report any revenue for the quarter.
Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/05/spry-stock-earnings-ars-pharmaceuticals-for-q1-of-2024/.
©2024 InvestorPlace Media, LLC